Eli Lilly Partners with Camurus in $870 Million Deal to Develop Long-Lasting Obesity Treatments

Eli Lilly has entered into a partnership with Swedish pharmaceutical company Camurus to explore the development of long-lasting obesity treatments. The agreement, valued at up to $870 million, grants Lilly access to Camurus’ proprietary drug delivery technology. This technology is designed to enhance the durability and effectiveness of medications, potentially extending the impact of up to four of Lilly’s weight-loss drugs.

The collaboration aims to leverage Camurus’ expertise in advanced drug delivery systems, which are known for their ability to provide sustained therapeutic effects over extended periods. By integrating this technology into its portfolio, Lilly seeks to address growing demand for innovative solutions in obesity management. Financial terms include milestone payments tied to development progress and commercialization success, underscoring the strategic importance of this partnership for both companies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 4, 2025

Related posts:

AI and 3D Printing Boost Generic Drug Development, Expanding Formulation Possibilities Generic Drug Stability Testing Follows FDA Guidelines to Ensure Medication Quality and Safety STAT’s D.C. Diagnosis Newsletter Delivers Twice-Weekly Health Policy Insights Teenage years crucial for depression intervention, study finds

Author

Mark Chiang